Skip to main content
Premium Trial:

Request an Annual Quote

Precision Oncology Resources: Webinars

Thu
Jul
25
11:30 AM
US Eastern

Sponsored by Guardant Health

Panel Talk: Unlocking Global Access to Liquid Biopsy Through In-Country Testing

Enabling global access to precision medicine with liquid biopsy CGP testing has been challenging. Obstacles include standardizing a complex liquid biopsy testing workflow globally and varying regional healthcare guidelines and regulatory policies.

In this panel discussion, Jean-Francois Martini, head of biomarker clinical assay and technology at Pfizer, and Lawrence Wang, chief financial officer at Adicon, will take a deep look into challenges, considerations, and breakthroughs in enabling access to the China population for global clinical trials. Vafa Amirkia, Guardant Health’s director of biopharma business development in China, will lead the discussion.

Following the discussion, Simranjit Singh, CEO of the Asia, Middle East, and Africa (AMEA) regions at Guardant, will highlight how the company has successfully enabled in-country access to their robust, validated liquid biopsy technology for patients around the world.

The discussion and presentation will be followed by an audience Q&A.

Sponsored by

guardantHealth-master-logo-PR-620x315.jpg
Tue
Aug
27
11:00 AM
US Eastern

Sponsored by Pillar Biosciences

Accelerating Access to Liquid Biopsy Testing With Kitted NGS Solutions

To date, liquid biopsy testing has largely been provided by large centralized CLIA reference laboratories. To help maximize global access to liquid biopsy and associated targeted therapies, biopharmaceutical organizations are interested in establishing diagnostic partnerships to drive liquid biopsy testing at local and regional laboratories, leveraging in-house NGS platforms to provide testing closer to patients, enabling more timely, efficient, and cost-effective care.

In this webinar, John Longshore, head of scientific affairs for global oncology diagnostics at AstraZeneca, and Pantelis Constantoulakis, the scientific director at Genotypos Science Labs, will discuss:

 

  1. The importance of liquid biopsy testing in guiding access to precision therapies and clinical trials.
  2. The challenges faced by global pharmaceutical companies regarding patient access to liquid biopsy and new strategies to improve access.
  3. A laboratory evaluation of the performance, workflow, and cost of Pillar Biosciences’ suite of kitted liquid biopsy-based assays.

Sponsored by

Thu
Sep
19
11:00 AM
US Eastern

Advances in Single Cell and Spatial Biology

Learn how single-cell genomics and spatial biology are poised to advance precision medicine at PMLS Advances in Single Cell and Spatial Biology, to be held September 19 – 20, 2024, in San Diego. 

Single-cell and spatial omics technologies have provided unprecedented insights into tissue heterogeneity and biological complexity, driving new opportunities in genomic medicine. These complementary approaches have converged in recent years to create a new toolkit of methods to explore the spatial position of molecular features in a cell or tissue. 

While single-cell RNA-sequencing experiments map transcripts to individual cells, the positions of these transcripts within the tissue are not always known. And spatial transcriptomics can elucidate the location of transcripts but not always the cell that produced them. Studies using these techniques alone or in combination are producing a wealth of data to advance the fields of developmental biology, cancer, immunology, and neuroscience.

Join us to hear important insights from pioneers in single-cell and spatial omics. This two-day event, part of the 2024 Precision Medicine Leaders’ Summit series, will feature high-level discussions and ample networking opportunities with experts from key research organizations, cancer institutes, pathology labs, technology developers, and pharmaceutical executives who are driving innovation in the field and advancing the implementation of these methods into patient care.

Tue
Oct
15
9:00 AM
US Eastern

Precision Oncology & Diagnostics

This event, developed with guidance from the editorial team of Precision Oncology News, will focus on the rapidly evolving field of precision oncology, including new diagnostic and therapeutic modalities, regulatory and reimbursement trends, and implementation challenges.

PMLS Precision Oncology and Diagnostics 2024 will bring together key stakeholders to discuss strategies and best practices for implementing molecularly guided cancer care. Thought leaders from pharmaceutical and biotech firms, leading cancer centers, and the research community will share real-world experiences in delivering precision oncology to patient populations.

Anyone tracking the opportunities and challenges associated with individualized cancer therapy will want to attend this event, including oncologists, pathologists, health system executives, regulatory and reimbursement experts, clinical researchers, and pharmaceutical/biotech executives.

Tue
Dec
31
11:30 AM
US Eastern

test event

overview

Wed
Jun
25
11:30 AM
US Eastern

On Demand: Multiomics in Precision Medicine 2024

This event, part of the Precision Medicine Leaders’ Summit conference series and developed in partnership with the University of Pennsylvania Institute for Biomedical Informatics, took place June 25 - 26, 2024

The conference explored how multiomics methods are advancing precision medicine in a range of human disease areas.

Recent advances in multiomic approaches — including genomics, transcriptomics, epigenomics, proteomics, and metabolomics — enable a more comprehensive picture of disease biology. This promises to accelerate the development of precision medicine, but also presents challenges for researchers, clinicians, and health systems struggling to integrate disparate data sources into a cohesive clinical strategy.

Multiomics in Precision Medicine 2024 highlighted best practices, trends, and strategies from experts who are successfully implementing a range of omics approaches to advance molecularly informed medicine.